Introduction
============

Cancer is the third leading cause of death in the world and mortality is expected to rise [@B1], [@B2]. Despite current state-of-the-art treatment options, many cancer patients will ultimately die due to metastatic disease. In the last few decades, new insights in biological processes underlying cancer led to a flood of rationally designed targeted drug candidates [@B3]. However, these targeted agents have not reached their full potential due to inadequate patient selection, which may partly be solved by enrichment of patient populations using specific biomarkers [@B3]. Underlying reason for these patient sub-populations is inter-tumor heterogeneity caused by genotypic and phenotypic differences between tumors of similar histopathological subtype [@B4]. Similarly, within and between tumor lesions of a single patient (intra-tumor heterogeneity), drug target and biomarker expressions are neither homogeneous nor static [@B4]. Thus, high degrees of intra-tumor heterogeneity in acquired mutations and target expression levels can lead to clonal heterogeneity, an outgrowth of treatment-resistant cells, and ultimately, treatment failure [@B5], [@B6]. Furthermore, pathway rewiring can lead to acquired resistance. Combined, these factors prevent or circumvent efficacy of targeted drugs [@B7], requiring advanced detection tools to determine tumor heterogeneity, biomarker expression dynamics for improving patient selection, and monitor treatment efficacy. In this review, we will discuss how molecular imaging may complement molecular testing to facilitate patient selection and monitor drug efficacy. We will also review discovery platforms for novel imaging markers that signify response or resistance to molecularly targeted treatments.

Molecular imaging is well-suited for visualization and clinical assessment of biological processes, as it can non-invasively and quantitatively monitor whole-body marker expression [@B8], [@B9]. By comparing the uptake of imaging tracers across all lesions and between patients, the tumor heterogeneity, drug delivery, and biological responses to drug treatment can be assessed before clinical progression becomes apparent by conventional techniques, *e.g.* biopsies and anatomical imaging [@B8]. Furthermore, molecular imaging has the potential to monitor \'effect sensors\', early response biomarkers providing insight into the functional changes at the cellular level that reflect the effectiveness of treatment or emergence of resistance mechanisms.

We will also explore various techniques and platforms that can be utilized for identification, selection and molecular imaging of drug targets and effect sensors. The role of the human epidermal growth factor receptor (HER) family in human cancers has been extensively studied. Consequently, multiple HER-targeted agents are in clinical use and many HER-targeted imaging strategies and resistance mechanisms have been reported [@B10]. Therefore, we will use the known crosstalk, resistance mechanisms and effect sensors of the HER family as a model.

Search Strategy
---------------

Public data base searches were performed on PubMed, ClinicalTrials.gov and Google Scholar for combinations of the following search terms: "EGFR", "HER2", "HER3", "HER4", "c-MET", "VEGF-A", "Src", "ImmunoPET", "PET", "SPECT", "molecular imaging", "fluorescence imaging", \'\'near-infrared", "nuclear imaging", \'\'optoacoustic imaging", "resistance", "breast cancer", "lung cancer", "gastric cancer", "colorectal cancer", "systems biology", "integrative omics", "genomics", "transcriptomics", "proteomics", "mass spec", "biomarker", and "treatment response".

Important abbreviations
-----------------------

**Protein-related;**EGFR: epidermal growth factor receptor; HER: human EGFR family; HER2-4: human EGFR 2-4; RTK: receptor tyrosine kinase; c-MET: cellular-mesenchymal to epithelial transition factor; HSP90: heat shock protein-90; Src: Rous sarcoma oncogene cellular homolog

**Cancer-related;**CRC: colorectal cancer; NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinoma**;**TKI: tyrosine kinase inhibitor; mAb: monoclonal antibody

**Imaging;**SPECT: Single photon emission computed tomography; PET: positron emission tomography; CT: computed tomography; Zr: zirconium; In: indium; Ga: Gallium; Cu: Copper; Tc: technetium; I: iodine; F: fluorine; C: carbon; NIRF: near-infrared fluorescence; 800CW: IRDye 800CW

**Omics;**CNAs: copy number aberrations; PTMs: post-translational modifications; MS: mass spectrometry; TCGA: The Cancer Genome Atlas consortium

HER family pathways and resistance in cancer
============================================

HER family signaling
--------------------

To understand how HER-targeted imaging strategies could potentially benefit patients, it is important to identify the HER-mediated signal transductions, which are the underlying processes determining treatment efficacy. The HER family consists of four receptor tyrosine kinases (RTKs); epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 (also ERBB1-ERBB4). HER members function through homo- or heterodimerization to stimulate proliferation, cell survival, and metastasis (Figure [1](#F1){ref-type="fig"}A) [@B11]. Like most RTKs, HER proteins comprise an extracellular ligand-binding domain and an intracellular ATP-dependent tyrosine kinase (TK) domain. Ligand-induced conformational changes in HER family proteins allow for dimerization, which promotes transphosphorylation of tyrosine residues in TK domains of dimerization partners leading to downstream protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) pathway activation [@B12],[@B13]. Various ligands non-exclusively bind to EGFR, HER3 and HER4, as listed in Figure [1](#F1){ref-type="fig"}C [@B11]. In contrast, no ligand is known to bind HER2. Rather, HER2 conformation allows constitutive dimerization making it the preferred dimerization partner for other HER family members [@B14]. HER3 only has weak intrinsic kinase activity and thus mainly depends on heterodimerization for phosphorylation of six unique tyrosine residues in the C-terminal tail, initiating potent downstream signaling [@B15]-[@B17].

HER family receptors in cancer and treatment resistance
-------------------------------------------------------

HER ligands are aberrantly expressed in various cancers and HER family members, especially EGFR and HER2, are oncogenic drivers upon mutation or amplification (Figure [1](#F1){ref-type="fig"}) [@B10]. Therefore, several HER-directed therapeutics have been developed including small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) (Figure [1](#F1){ref-type="fig"}B) [@B10]. The HER2 mAb trastuzumab increases overall survival of patients with metastatic disease and of patients with HER2-positive breast cancers in the adjuvant setting [@B18]. Nevertheless, resistance to HER-directed treatments frequently occurs (Figure [1](#F1){ref-type="fig"}C). Resistance can develop from selective pressure on existing or *de novo* mutations, which circumvent drug action [@B19]. Alternatively, treatment resistance can develop through rewiring of parallel signaling pathways often involving other RTKs taking over the proliferative drive [@B19]-[@B24]. Although not all mechanisms of treatment resistance are understood, multiple mechanisms that drive resistance to HER-directed agents have been elucidated underscoring the need for preventive and alternative treatment strategies.

Treatment with EGFR-directed mAbs cetuximab or panitumumab shows anti-tumor efficacy in a subset of colorectal cancer (CRC) patients harboring *KRAS* wild-type (wt) tumors while EGFR TKIs gefitinib or erlotinib are not effective due to the absence of mutations in *EGFR* [@B10]. In CRC patients with *EGFR*-wt tumors, resistance to EGFR-directed therapeutics can emerge through selection or *de novo* acquisition of oncogenic *KRAS* mutations [@B25]. In contrast to CRC, treatment with EGFR-mAbs in non-small cell lung cancer (NSCLC) hardly improves clinical outcomes. Yet, treatment with gefitinib and erlotinib has an anti-tumor effect in NSCLC patients harboring activating mutations in the *EGFR* TK domain [@B26]. Invariably, these patients develop resistance, which in \~60% of the patients, is due to the *EGFR*-T790M \'\'gatekeeper\'\' mutation that renders EGFR insensitive to both gefitinib and erlotinib (Figure [1](#F1){ref-type="fig"}C) [@B26]. To counter this mechanism, second and third generation EGFR TKIs with increased affinity for *EGFR-*T790M are in development. The TKI afatinib, approved for *EGFR*-exon 19 deletions or exon 21 L858R substitutions in NSCLC, is also being evaluated in combination with cetuximab in NSCLC patients harboring T790M mutations. [@B27], [@B28]. The EGFR*vIII* mutation, which lacks the ligand-binding domain encoded by exons 2-7 leading to constitutive kinase activity, is mainly found in glioblastoma multiforme. The lack of a ligand-binding domain and absence of kinase mutations make that EGFR*vIII*mutant cancers respond poorly to TKIs and EGFR mAbs regardless of mAb ability to bind to the receptor [@B29].

In breast cancer, HER2 is an oncogenic driver with 20-25% of breast cancers harboring *HER2* amplification and are classified as HER2-positive. Compared to amplifications, *HER2* mutations are rare. Nevertheless, these mutations are found in \~2% of NSCLCs and may render tumors amenable to HER2-directed therapy [@B30]. Multiple underlying mechanisms have been described for HER2-directed trastuzumab treatment resistance. For instance, expression of a truncated p95-HER2 isoform hampers binding of trastuzumab to HER2 and results in clinical trastuzumab resistance [@B31], [@B32]. Alternatively, resistance can develop through increased signaling from other RTKs, including EGFR, HER3, insulin-like growth factor receptor (IGF1R), and cellular-mesenchymal to epithelial transition factor (c-MET) [@B33]. Since trastuzumab does not prevent interaction between HER2 and other RTKs, the HER2-directed mAb pertuzumab was developed to prevent dimerization by blocking the HER2-dimerization domain [@B34]. In light of this, the addition of pertuzumab to trastuzumab and docetaxel as first-line treatment resulted in a longer overall survival of patients with metastatic breast cancer [@B35]. Furthermore, a trastuzumab-based antibody-drug conjugate (ADC), ado-trastuzumab emtansine (T-DM1), was developed to deliver a potent maytansinoid toxin payload to HER2-positive cells. Treatment with T-DM1 showed an overall survival benefit in patients with HER2-positive breast cancers and tumor responses were seen in patients who had developed trastuzumab resistance [@B36]. Thus, novel treatment and combination strategies, such as the addition of pertuzumab or using ADCs, can limit or circumvent resistance to trastuzumab.

Although overlooked for a long time, HER3 received interest as a drug target when somatic mutations were discovered in breast and gastric cancers, and when a role for HER3 signaling as a resistance mechanism to HER-directed therapeutics was revealed [@B37]. Specifically, when HER family members are targeted by TKIs, HER3 can re-activate downstream signaling, ultimately shifting signaling towards increased phosphoinositide-3 kinase (PI3K) /AKT activity and increased HER3 expression [@B20],[@B21]. Indeed, resistance to the EGFR/HER2-directed TKI lapatinib in HER2-positive breast cancer cell lines was the result of increased EGFR-HER3 signaling complexes induced by autocrine secretion of HER3 ligand NRG1 (Figure [1](#F1){ref-type="fig"}C). Notably, NRG1 expression was a negative predictor of lapatinib treatment, suggesting binding of NRG1 to EGFR-HER3 complexes as a potential cause of resistance [@B22]. As the TK domain of HER3 is virtually inactive, drug design for HER3-targeted therapies mainly focuses on preventing dimerization using mAbs, which are currently being clinically evaluated [@B37]. Additionally, changes in HER3 expression or activation might serve as an early readout of resistance to EGFR or HER2 therapy.

Resistance mechanisms through non-HER family receptors and downstream signaling nodes
-------------------------------------------------------------------------------------

HER family members also interact with non-HER family members [@B23], [@B38]. The crosstalk between RTKs and downstream signaling nodes compose of feedback activation loops leading to intriguingly complex signaling networks. This diversity also underlies many resistance mechanisms to drugs that target single components of this signaling network and could be potential imaging targets to monitor treatment efficacy.

One dimerization partner that can drive resistance to HER-targeting drugs is c-MET, a RTK that promotes growth, metastasis, and angiogenesis [@B39]. Binding of the ligand hepatocyte growth factor/scatter factor (HGF/SF) to c-MET leads to homodimerization, autophosphorylation, and downstream signaling through PI3K and AKT [@B40] making c-MET a prime suspect for alternative signaling after EGFR blockade [@B23], [@B40]. Indeed, resistance to cetuximab or gefitinib in head and neck squamous cell carcinoma (HNSCC) and NSCLC cell lines involved *MET* amplification and subsequent heterodimerization of HER3 with c-MET (Figure [1](#F1){ref-type="fig"}C) [@B23],[@B24]. Furthermore, in preclinical studies, HGF-induced c-MET signaling resulted in resistance to gefitinib in NSCLC and lapatinib in breast cancer cell lines [@B19], [@B41]. These reports signify that dual targeting of c-MET and EGFR might be necessary to prevent the emergence of resistance. Preliminary *in vitro* results have indeed shown synergistic effects of combined inactivation of EGFR and c-MET in HNSCC and NSCLC cell lines [@B23], [@B42], [@B43]. Several c-MET targeting agents ranging from TKIs, antibodies against c-MET, as well as antibodies against the c-MET ligand HGF are currently in phase III clinical trials [@B44].

Another player in HER family signal transduction is Rous sarcoma oncogene cellular homolog (Src), a non-receptor TK that regulates cell growth, migration, and survival signaling pathways. Src interacts with EGFR and HER2 as well as with c-MET, IGF1R, platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) [@B45]. Binding of Src to HER2 conferred resistance to trastuzumab in human tumor cell line models harboring a *HER2-*exon 16 deletion (Figure [1](#F1){ref-type="fig"}C) [@B46]. In another study, Src activation conferred resistance to erlotinib *in vitro* and *in vivo* by inducing c-MET expression in HNSCC models, which could be rescued by genetic or pharmacological inactivation of c-MET [@B47] indicating that Src, at least in the selected *in vitro* models, is a key regulator of c-MET-mediated resistance to HER-targeted agents.

Compensatory signaling upon EGFR inhibition can also be mediated by IGF1R. Considerable overlap has been observed in the functions of IGF1R and the HER family and upregulation of the IGF1R signaling axis has been observed to compensate for the loss of HER signaling [@B48]. In a retrospective study of 155 patients with HER2-positive breast cancers treated with trastuzumab as an adjuvant, increased expression of EGFR and IGF1R and dysregulation of the AKT pathway were observed following the failure of neoadjuvant or conventional therapy and were associated with worse treatment outcome [@B49]. In line with these results, IGF1R activation and dimerization with HER2 was observed in a trastuzumab-resistant clone of the human breast cancer cell line SKBR3 but not its parental trastuzumab-sensitive cell line [@B38]. Furthermore, resistance to irreversible EGFR TKIs was mediated through activation of the IGF1R pathway in PC9 NSCLC cells [@B48]. Also, epigenetic alterations were shown to drive IGF1R engagement in a human cancer cell lines panel, causing transient resistance to gefitinib, erlotinib, cisplatin and BRAF inhibitor treatment [@B50].

Taken together, a theme emerges in which inactivation of key HER family members results in strong positive feedback on various other RTKs, including c-MET, IGF1R, and Src. Ultimately, this rewiring restores proliferation and survival signaling and results in treatment-resistant clones. How this positive feedback is wired at the molecular level is unclear, although it seems to converge at reinstating AKT or ERK signaling.

Also, when downstream signaling components of the HER pathway are targeted, rapid rewiring and activation of parallel pathways were observed. Inhibition of PI3K in HER2-positive cell lines resulted in activation of FOXO transcription factors and upregulation of HER3 [@B48], which was similar to HER2 inhibition [@B20]. Also, PI3K inhibition in HER2-overexpressing human breast cancer xenografts resulted in acquired dependency on ERK signaling [@B51]. Further, inhibition of AKT, the critical downstream target of PI3K, induced HER3 expression and activation of HER3, IGF1R, and the insulin receptor (IR) in human breast cancer, prostate cancer, and NSCLC cell lines [@B52]. Likewise, treatment of breast cancer cell lines with the mechanistic target of rapamycin (mTOR) inhibitor AZD8055 resulted in induction of HER proteins and activation of HER3 specifically [@B53]. The aforementioned resistance mechanisms underscore the plasticity of the HER family and parallel signaling networks and warrants the development of non-invasive diagnostic tools that can be applied serially to identify not only which tumors respond to anti-HER drugs but also when resistance to these agents develops.

Molecular imaging strategies
============================

Here, we will discuss how molecular imaging strategies might be employed to improve HER family-directed treatment with a focus on marker-selective imaging agents. Besides imaging generic cancer processes such as glucose metabolism with ^18^F-FDG or proliferation by ^18^F-FLT, marker-selective imaging agents can capture a broad range of cancer hallmarks [@B54], which might be informative for the efficacy of HER-directed treatment.

Molecular imaging can be performed by various modalities, *e.g.* radionuclide, optical, optoacoustic and magnetic resonance imaging, with each modality having unique advantages as well as limitations [@B8]. Molecular imaging with radionuclides is the most widely used technique. The main attractive features of radionuclide-based imaging are high signal sensitivity and the ability to non-invasively acquire quantitative three-dimensional information of whole body tracer distribution. For single photon emission computed tomography (SPECT) imaging, a three-dimensional image is computed from multiple two-dimensional images taken at different angles of a gamma ray-emitting radioisotope. On the other hand, when multiple detectors are used, positron emission tomography (PET) imaging can be inherently three dimensional, based on the origin of the two near-perpendicular 511 keV gamma rays emitted after positron annihilation. In contrast to SPECT, physical collimators are not necessary for PET resulting in higher sensitivity, spatial resolution, and corresponding shorter acquisition time for scans allowing more temporal resolution to study dynamic features [@B55].

Accurate quantification of cellular receptor levels using molecular imaging agents can be affected by - but not limited to - a variety of factors such as blood flow, vascular permeability, vascularization, lymphatic drainage, cellular internalization rate, non-specific binding, blood and interstitial pressure, metabolites, number of binding-sites, the enhanced permeability and retention effect, as well as tracer pharmacokinetics [@B56], [@B57]. Additional complications in quantification, can come from external sources such as respiration movements of the subject as well as differences between scanners, settings, and reconstruction algorithms. The partial volume effect, image blurring due to the finite resolution of the scanner, and target heterogeneity within the tissues contained in the smallest resolution unit (i.e. pixels, voxels) can also affect the accuracy of quantification [@B57]. To resolve these issues, efforts have been directed towards more accurate quantification of molecular imaging data, a subject that has been expertly reviewed by others [@B56], [@B57].

Radioisotopes for SPECT and PET imaging can be incorporated in targeting molecules in various ways, *e.g.* through covalent binding or chelation. Selection of the most appropriate radioisotope is based on the physical half-life of the radionuclide, which should match the biological half-life of the imaging agent to balance optimal time for tracer accumulation in lesions with sufficient signal strength, while minimizing radiation burden. For instance, carbon-11 (^11^C, t~1/2~= 20 min, PET) and fluorine-18 (^18^F, t~1/2~= 110 min, PET) are often used to label small molecules, with little or no alteration of their kinetic parameters. In contrast, high molecular weight biomolecules, such as antibodies, need relatively long-lived radiometals for optimal contrast, such as zirconium-89 (^89^Zr, t~1/2~= 78.4 h, PET), indium-111 (^111^In, t~1/2~ = 67.3h, SPECT) or radiohalogen iodine-124 (^124^I, t~1/2~= 100.3 h, PET). Fluorine-18, as well as radiometals copper-64 (^64^Cu. t~1/2~= 12.7 h, PET), technetium-99m (^99m^Tc, t~1/2~= 6.0 h, SPECT) and galium-68 (^68^Ga, t^1/2^ = 68 min, PET) are well-suited for imaging biomolecules with short biological half-lives.

Besides radionuclide-based imaging, optical methods such as near-infrared fluorescence (NIRF) and optoacoustic imaging have received increasing attention. These techniques combine high resolution with real-time signal acquisition in the field of view. Advantages of optical methods compared to radionuclide-based imaging are the lack of radiation burden to patients, \'\'off the shelf\'\' availability of tracer molecules, and relatively low costs. Limitations of optical imaging include the difficulty of signal quantitation, limited penetration depth, and a restricted field of view. Optical methods, therefore, appear most suited for localized organ-level imaging, such as intra-operative or endoscopic imaging.

Molecular imaging capabilities are rapidly expanding and many known processes and pathways that comprise the hallmarks of cancer can be visualized using PET or SPECT tracers [@B54]. In this context, molecular imaging can be used to non-invasively determine lesion biomarker status to facilitate proper patient selection. Labeled drugs or analogs thereof can be used to assess drug accumulation across lesions. Many HER family targeting tracers have been described in the literature. The tracers mentioned in this review highlight the most important findings within each imaging strategy, and are listed in Table [2](#T2){ref-type="table"}. For a systematic overview of HER-targeted tracers, we refer to excellent reviews by others [@B58],[@B59].

Target expression imaging
-------------------------

Molecular imaging may be used in the clinical setting to measure HER family expression status in multiple tumor lesions simultaneously and to visualize the inter-tumor heterogeneity. Measuring multiple lesions at once might be relevant as single biopsies or small tumor fractions are not an adequate representation of all lesions [@B60]. Whether molecular imaging can be used to better predict response to EGFR-targeted agents is unresolved. However, several animal studies showed a correlation between EGFR expression of human cancer xenografts and uptake of ^64^Cu-cetuximab, ^111^In-cetuximab and ^111^In-f(ab\')~2~-cetuximab [@B61]-[@B63]. Other preclinical studies, however, found discordance between xenograft EGFR expression and ^89^Zr-cetuximab or ^64^Cu-cetuximab accumulation. In these studies, EGFR overexpression did not necessarily result in corresponding high tumor tracer accumulation, suggesting that factors other than EGFR expression, such as perfusion and vascular permeability might influence cetuximab-based tracer tumor uptake [@B64], [@B65]. For instance, in a preclinical study circulating shed EGFR ectodomain (sEGFR) influenced the kinetics and tumor targeting of the EGFR antibody tracer ^89^Zr-imgatuzumab [@B66]. In a patient study, six out of 10 metastatic CRC patients showed ^89^Zr-cetuximab tumor uptake when administered with a therapeutic dose of cetuximab. Four of these six patients had clinical benefit of cetuximab therapy, while a progressive disease was observed in three out of four patients without ^89^Zr-cetuximab uptake [@B67]. Although promising, larger cohorts should be screened to establish the value of ^89^Zr-cetuximab for prediction of cetuximab efficacy in metastatic CRC colorectal cancer patients (NCT02117466).

The EGFR TKIs erlotinib and gefitinib display higher affinity for oncogenic *EGFR* mutants. This feature can be exploited to selectively image mutant *EGFR* variants and provides an attractive tool for assessing heterogeneity in *EGFR* mutation status. In several preclinical studies, there was a higher accumulation of ^11^C-erlotinib in NSCLC and glioma xenografts containing activating *EGFR* mutations in exon 19 and 21 when compared to xenografts of erlotinib-resistant *EGFR*-T790M, *EGFR*-wt, or *EGFR* with activating mutations in its extracellular domain [@B68]-[@B70]. The ^11^C-erlotinib volume of distribution was higher in patients with NSCLC lesions with *EGFR* activating exon 19 deletion than in lesions from patients without activating mutations (Figure [2](#F2){ref-type="fig"}D, E) [@B71]. In another series of 13 NSCLC patients, three out of four patients with ^11^C-erlotinib PET positive lesions responded to erlotinib treatment while the best response seen in in two out of nine patients with ^11^C-erlotinib PET negative lesions was a stable disease [@B72]. A case report showed high ^11^C-erlotinib uptake in brain metastases of a NSCLC patient with an exon 19 mutation in the primary tumor with response to erlotinib in both primary tumor and brain metastases, underscoring the potential value of mutant-specific imaging of *EGFR* status [@B73]. Imaging with the pan-HER TKI afatinib can also be used to visualize receptor mutation status. Analysis of ^18^F-afatinib showed higher accumulation in A549 *EGFR*-wt and HCC827 *EGFR-*exon 19 deletion compared to H1975 *EGFR-*T790M human NSCLC cell line xenografts. This reflects the affinity of afatinib to *EGFR* with activating mutations [@B74].

Analogously, several preclinical imaging studies have been performed to visualize *EGFRvIII* status. Specifically, IRDye 800CW (800CW)-panitumumab and an 800CW-EGFR affibody bound to *EGFR*-wt and *EGFRvIII*with similar affinity in a rat glioma model. In contrast, 800CW-labeled EGFR ligand EGF identified *EGFR*-wt but not EGFR*vIII*-expressing lesions, reflecting the compromised EGFR*vIII* ligand-binding pocket [@B75]. In another study, the ^124^I-IMP-R4-labeled EGFR*vIII*-specific antibody ch806 was tested in human glioblastoma EGFR*vIII*-transfected U87MG xenografts expressing EGFR*vIII;* no preferential imaging of EGFR*vIII* could be established since only *EGFRvIII*cell lines were used [@B76]. Another EGFR*vIII*-specific antibody, ^99m^Tc-labeled 3C10, displayed over ten-fold higher accumulation in *EGFRvIII*-transfected U87MG human glioblastoma xenografts compared with the parental U87MG [@B77]. Furthermore, the IRDye 680RD-labeled EGFR*vIII* antibody biotin-4G1 accumulated more in EGFR*vIII*-expressing F98npEGFR*vIII* than in *EGFR*-wt F98npEGFR rat glioblastoma xenografts [@B78]. Overall, evidence exists that EGFR*vIII* might be distinguished from *EGFR*-wt using EGFR*vIII* tracers. However, more rigorous preclinical and clinical data and relevance are required to move this field forward.

Research on fluorescently labeled proteins recognizing EGFR mainly focused on their use as an add-on \'red flag\' technique for intraoperative and endoscopic procedures. Both 800CW-cetuximab and 800CW-panitumumab were tested for detection of breast cancer xenograft lesions [@B79]. Also, EGFR nanobody 800CW-7D12 could detect EGFR-overexpressing A431 human squamous cell carcinoma xenografts [@B80]. In a preclinical intraoperative study, 800CW-7D12 could visualize orthotopic primary tongue tumor xenografts and resulting cervical lymph node metastases which were otherwise not detectable with the naked eye [@B81]. Also, 800CW-cetuximab was successfully used to detect EGFR-positive lesions in a preclinical simulated colonoscopy of a resected human colon with human EGFR-expressing colon cancer HCT116^luc^xenografts stitched into the colon wall [@B82]. 800CW-cetuximab was likewise tested in HNSCC patients during surgery using wide-field NIR imaging. In these patients, tumor-to-background ratios of 4.3 and 5.2 were observed at 3 to 4 days after infusion of 25 and 62.5 mg/m^2^ doses of 800CW-cetuximab respectively [@B83]. There was a correlation between the fluorescent signal of 800CW-cetuximab and EGFR density in excised HNSCC tumors as determined by IHC [@B84]. To establish the clinical value of EGFR-targeted tracers, multiple clinical studies with 800CW-cetuximab and 800CW-panitumumab for intraoperative procedures and ^89^Zr-cetuximab, ^11^C-erlotinib, and ^89^Zr-panitumumab for EGFR PET imaging are currently pursued (Table [1](#T1){ref-type="table"}).

HER2 overexpression in breast cancer is associated with worse prognosis, if not treated with HER2-directed therapy [@B85]. HER2 has therefore been extensively studied as an imaging target to select patients for HER2-directed therapy (Figure [2](#F2){ref-type="fig"}A). ^89^Zr-trastuzumab as well as ^89^Zr-pertuzumab showed specific uptake in HER2-positive xenografts in mice [@B86]-[@B88] while ^111^In- and ^89^Zr-trastuzumab, ^111^In- and ^68^Ga-labeled HER2 affibodies and a ^68^Ga-HER2-nanobody have been applied in patients diagnosed with HER2-positive breast cancer [@B89]-[@B94]. ^64^Cu- and ^89^Zr-trastuzumab and ^68^Ga-ABY-025 PET are currently being tested for their value in identifying HER2-positive lesions and heterogeneity in breast and gastric cancer patients (Table [1](#T1){ref-type="table"}).

As discussed above, HER3 has been implicated in many escape mechanisms from HER family-targeted therapies. Therefore, early identification of changes in HER3 expression might serve to identify patients at risk of HER3-mediated treatment resistance and possibly for selection of patients eligible for HER3-targeted treatment. HER3 expression levels have been successfully imaged *in vivo* with the antibody ^89^Zr-lumretuzumab [@B95] and ^64^Cu-DOTA-HER3 F(ab\')2 [@B96], as well as ^99m^Tc-, ^111^In- and ^68^Ga-labeled HEHEHE-Z08698 and HEHEHE-Z08699 affibodies [@B97]-[@B99] while bispecific HER2/HER3 tracer ^111^In-DTPA-Fab-PEG24-HRG, based upon heregulin and a trastuzumab Fab, showed HER3 and HER2-mediated uptake in SK-OV-3, MDA-MB-468 and BT474 xenografts [@B100]. HER3 imaging has been studied clinically with ^64^Cu-patritumab, revealing tumor uptake in cancer patients, as well as high liver uptake which could be saturated with pre-administration of 9 mg/kg cold patritumab [@B101]. In imaging studies of patients, ^89^Zr-lumretuzumab showed a decrease in tracer tumor uptake after administration of 400, 800 and 1600 mg flat doses of unlabeled lumretuzumab when compared to a pre-dosing ^89^Zr-lumretuzumab scan with a 100 mg protein dose [@B102]. Another HER3 antibody tracer, ^89^Zr-GSK2849330, is currently being studied in the clinic (Table [1](#T1){ref-type="table"}).

Imaging of drug accumulation in tumors
--------------------------------------

Several imaging probes do internalize after binding to their targets. Radiometals^64^Cu, ^68^Ga, ^89^Zr, and ^111^In have residualizing properties, because these highly charged isotopes will remain trapped in cells after tracer internalization and subsequent catabolization resulting in accumulation of signal over time in antigen-expressing tissues. Radiohalogens such as ^18^F and iodine isotopes, and fluorescent dyes, on the other hand, are released from the cell after catabolization of the imaging probe. Residualizing probes will therefore roughly reflect the cumulative tracer exposure, while tracers using non-internalizing or non-residualizing isotopes approximate antigen density and binding capacity of the tracer over time.

An example of a non-residualizing approach is the antibody-photosensitizer conjugate IRDye 700DX (700DX)-cetuximab, which was effective in inhibiting tumor growth and could simultaneously image human triple negative breast cancer xenografts [@B103]. 700DX-cetuximab is currently being evaluated as dual imaging and treatment (theranostic) modality in patients with recurrent head and neck cancer (Table [1](#T1){ref-type="table"}). Use of a fluorescent approach to study drug accumulation might be feasible for lesions within the penetration depth of signal as well as during surgery or in endoscopic procedures. Accumulation of residualizing radioactive tracers in lesions, on the other hand, could be used as a proxy for antigen-specific delivery of the toxic payloads of ADCs and radio-immunotherapeutic agents. ^89^Zr-cetuximab was able to predict the accumulation of EGFR-directed radio-immunotherapeutics ^88^Y- and ^177^Lu-labeled cetuximab in A431 xenografts [@B104]. Furthermore, a ^64^Cu-labeled variant of MM-302, a HER2-targeting liposome containing doxorubicin, was successfully used to predict deposition, kinetics, and efficacy of the parental liposome in xenografts [@B105], [@B106]. An ongoing clinical trial assesses whether deposition of^64^Cu-MM-302 can predict the outcome of the doxorubicin-loaded parent liposome therapy in advanced breast cancer patients (Table [1](#T1){ref-type="table"}). A similar approach was already used in 56 breast cancer patients receiving ^89^Zr-trastuzumab PET scans prior to T-DM1 therapy to determine intra/interpatient HER2 heterogeneity and to identify non-responding patients. In this study, 28 out of 39 ^89^Zr-trastuzumab PET-positive patients responded to T-DM1 therapy, while 14 out of 16 of ^89^Zr-trastuzumab PET-negative patients had a stable or progressive disease [@B107]. These results indicated that ^89^Zr-trastuzumab might be used to identify patients who benefit from T-DM1 therapy. In another study, ^89^Zr-labeled MMOT0530A, the naked antibody component of the mesothelin-ADC DMOT4039A, accumulated preferentially in human pancreatic cancer xenografts [@B108].^89^Zr-MMOT0530A was further tested in 11 patients with ovarian or pancreatic cancer, revealing a large degree of heterogeneity of lesion tracer uptake, while PET uptake 4 days post injection correlated with IHC staining for mesothelin on a per patient basis. However, the small patient sample precluded analyses of correlation between lesion ^89^Zr-MMOT0530A uptake and clinical response to the corresponding ADC DMOT4039A [@B109].

Important in this context, residualization of tracers can be modulated by therapeutic interventions. For instance, multiple antibodies targeting the same antigen could lead to enhanced residualization, as was shown for ^89^Zr-pertuzumab and concurrent trastuzumab administration in HER2-positive xenografted mice [@B110]. Decreased steric hindrance of HER2 after administration of mucolytic agent N-acetylcysteine increased the uptake of ^89^Zr-trastuzumab in MUC4-expressing JIMT1 human breast cancer model [@B111]. Interestingly, treatment with anti-angiogenic agents could affect uptake and accumulation of tracer through modulation of vascularization and permeability for macromolecular therapeutics such as antibodies [@B112], [@B113]. Specifically, uptake of either ^89^Zr-labeled trastuzumab, bevacizumab, or IgG control antibody in xenografts was decreased in animals treated with the vascular endothelial growth factor A (VEGF-A) antibody bevacizumab due to vascular normalization [@B112],[@B113]. We envision that molecular imaging strategies could be employed for rationally designing drug combinations to increase deposition of drugs in tumors and possibly increase efficacy, for instance of ADCs. Importantly, such strategies can also instruct which treatment combinations should be avoided.

Imaging treatment effects
-------------------------

As therapies often elicit changes in expression, membrane localization and dynamics of proteins, such changes could potentially be used as \'effect sensors\' to monitor treatment response (Figure [2](#F2){ref-type="fig"}F). Assessment of functional treatment effects has been performed by measuring cell membrane proteins and ligands for which expression is known to be modulated upon successful target engagement. As an example, the VEGF receptor (VEGFR) ligand VEGF-A was potently down-regulated after heat shock protein-90 (HSP90) inhibition and consequently led to a decreased uptake of ^89^Zr-bevacizumab in breast and ovarian cancer xenografts [@B114],[@B115]. Downregulation of VEGF-A can also be the result of mTOR inhibition by mTOR inhibitors such as everolimus and could be visualized using ^89^Zr-bevacizumab in mice and humans [@B116], [@B117]. Also, treatment with VEGFR1-3-targeting TKI, sunitinib, a TKI targeting VEGFR1-3 led to changes in VEGF-A tumor levels that could be effectively assessed by bevacizumab F(ab\')2-fragment ^89^Zr-ranibizumab in ovarian and colon cancer xenografts [@B118].

Besides measuring ligands, analysis of RTK expression has been used as an effect sensor for successful target engagement. For instance, PI3K inhibitor GDC-0941 and AKT inhibitor GDC-0068 led to upregulation of EGFR in HCC70 human breast cancer xenograft which could be visualized with a ^64^Cu-DOTA EGFR F(ab\')~2~fragment derived from cetuximab [@B119]. Afatinib treatment, on the other hand, lowered HER2 expression in a human gastric cancer N87 xenograft model in mice, which was visualized using ^89^Zr-trastuzumab [@B120]. Lapatinib, on the other hand, interfered with receptor dynamics by upregulating and stabilizing HER2 at the plasma membrane, ultimately leading to lower ^89^Zr-trastuzumab-F(ab\')~2~ tracer uptake in a breast cancer model [@B121]. HSP90 inhibition also downregulated RTKs such as IGF1R and HER2, which was effectively discriminated by ^89^Zr-mAb391 and ^89^Zr-trastuzumab by PET, respectively, as well as by AlexaFluor680-ZHer2:342 affibodies for HER2 with near-infrared fluorescence in breast cancer xenografts (Figure [2](#F2){ref-type="fig"}B) [@B115],[@B121]-[@B124]. This latter approach was clinically validated using HER2 as an effect sensor for treatment with HSP90 inhibitor NVP-AUY922 in HER2-positive breast cancer patients using ^89^Zr-trastuzumab PET and correlated with a response by computed tomography (CT) (Figure [2](#F2){ref-type="fig"}C) [@B125]. Also, inhibition of AKT by GDC-0068 led to an upregulation of HER3 in patient-derived triple negative breast cancer xenografts, which in turn increased dual EGFR/HER3 antibody ^89^Zr-MEHD7945A tumor uptake [@B126]. Selective imaging of HER3 upregulation after GDC-0068 treatment in MDA-MB-468 human breast cancer xenografts was demonstrated using ^64^Cu-DOTA-HER3 F(ab\')~2~(Figure [2](#F2){ref-type="fig"}F,G) [@B119]~.~

These are examples of HER family therapy effects that can be visualized and might be applied to adjust therapy in a timely fashion. However, only a few effects sensors are currently available to image treatment effects. This is partly because the effect sensor has to be excreted or expressed extracellularly to have accessibility to the target. This is due to the difficulty of high molecular weight imaging probes like antibodies, to cross the plasma membrane, and if required, the nuclear membrane.

Imaging Intracellular processes *in vivo*
-----------------------------------------

Visualization of intracellular targets has been largely restricted to small molecule-based imaging tracers. In general, intracellular processes for which imaging is currently feasible are generic processes such as tumor glucose metabolism by ^18^F-FDG and cellular proliferation using ^18^F-FLT and ^11^C-thymidine incorporation. One strategy to overcome the hurdle posed by the inability of antibodies to cross membranes, is modifying them with the HIV1-derived cell-penetrating transactivator of transcription (TAT) peptide, to ensure nuclear deposition (Figure [2](#F2){ref-type="fig"}H) [@B127]. Using this technique, ^111^In-anti-p27^kip1^-TAT antibody SPECT imaging was able to visualize upregulation of the nuclear localized cyclin-dependent kinase inhibitor p27^kip1^ after trastuzumab treatment of mice bearing human breast cancer xenografts [@B128]. More recently, this approach has also been applied for detection of DNA damage using a phospho-specific H2AX antibody in human breast cancer xenografts and during tumorigenesis in a transgenic BALB-*neu*T murine breast cancer model, ^111^In- and ^89^Zr-labeled TAT-modified phospho-H2AX antibody detected DNA breaks induced by chemo and radiotherapy (Figure [2](#F2){ref-type="fig"}H,I) [@B129]-[@B131].

Many targeted therapies aim to inactivate intracellular proteins, which currently are not accessible for high molecular weight imaging probes. Approaches similar to imaging with the TAT-modified phospho-H2AX antibody could be envisioned, where changes in the activity of intracellular signaling pathways, including altered activation status of AKT or MAPK, could be visualized. Imaging these targets might reveal whether the intended therapeutic inactivation of a specific intracellular target is achieved and sustained or whether signaling is reactivated or rewired. If the plasma membrane no longer posed a barrier in such strategies, the number of possible targets for high molecular weight probes would greatly increase. In such a scenario, imaging studies of prognostic or predictive markers could focus on the most relevant targets, and would no longer be restricted to proxies at the plasma membrane.

Radiomics
---------

The emerging field of radiomics combines imaging data with \'omics\' methodology. In radiomic analyses, quantitative features are mined from large data sets of (mainly routine) medical tomographic imaging data such as PET, CT and MRI scans using bioinformatics. Examples of features comprise, amongst others, descriptors for shape, size, volume and texture in space and over time, which in turn might reflect underlying pathophysiology. These features are combined with clinical outcome data and other patient characteristics to develop predictive models for genetic and molecular characteristics, prognosis, as well as treatment response [@B132], [@B133].

Tentative retrospective radiomics studies for prediction of HER tumor status have yielded encouraging results. A set of 11 radiomic features extracted from CT images of patients with lung adenocarcinoma was predictive for *EGFR* mutation status, with an area under the curve (AUC) of the receiver operating characteristic curve (ROC) of 0.667 for radiomic data alone, and 0.709 when combined with clinical parameters [@B134]. In another study, a decision tree based upon several CT textural features could differentiate *KRAS*mutants from *EGFR*-wt NSCLC patients with sensitivity, specificity, and accuracy of 96.3%, 81.0% and 89.6%, respectively [@B135]. Radiomic features extracted from ^18^F-FDG PET in NSCLC patients could discriminate mutant *EGFR* from *EGFR-*wt as well as mutant *EGFR* from *KRAS* mutants but could make no distinction between *KRAS* mutant and *EGFR*-wt [@B136]. To our knowledge, no radiomics studies with HER-targeted molecular imaging probes have been reported. However, future radiomic analysis of large databases of PET data from HER-targeted tracers, combined with clinical data, might help identify features for prediction of underlying patient phenotype and outcome.

Platform integration to guide selection of novel tracers
========================================================

Both the arsenal of available tracers as well as the technology for molecular imaging are advancing rapidly. However, molecular imaging can benefit from other disciplines for the identification of novel discriminating factors. In this regard, large data sets of biological information can increasingly be utilized for the identification of the most interesting and informative targets for imaging. Clinical and pre-clinical studies progressively include \'omics\' methodologies encompassing genomic, transcriptomic, and proteomic analyses. Combined with clinical outcome metrics these data yield an \'integrative omics\' approach. This offers great opportunities for extensive data mining to discover biomarkers which associate with tumor characteristics, treatment responses, and survival outcomes. These biomarker panels are not only useful to define new molecular-based tumor markers for molecular testing, but also provide a great resource to identify relevant molecular imaging targets, indicative of treatment effectiveness or resistance [@B137]-[@B139].

Clinical classification using integrative omics
-----------------------------------------------

Integrative omics can be applied to uncover key pathways that are altered in cancer by utilizing information from the \'cancer genome\' with an associated \'cancer proteome\' [@B140]. Often-used platforms include combinations of genomics (*i.e.* DNA sequencing for mutations, copy number aberrations (CNAs), and methylation of genes), transcriptomics (microarray RNA-based or RNAseq-based expression analysis), and proteomic analysis (proteins abundance and post-translational modifications (PTMs) using mass spectrometry (MS) or multiplexed reverse-phase protein arrays (RPPA)) (Figure [3](#F3){ref-type="fig"}) [@B141]. Because integrative omics approaches use unbiased selection methods, they are of potential interest for classification of patient groups and identification of biomarkers. Large-scale initiatives have attempted to diversify on histological cancer subtypes by identifying common features within the high information density of multiple platforms. For example, in-depth genomic analysis of 2,000 breast cancers identified 10 genetic classifications of breast cancer with distinct survival outcomes, although their clinical relevancy will need to be validated [@B142]. Reassuringly, in a study of over 6,000 breast cancer patients, expression profiling using a panel of 70 genes (MammaPrint) showed that adjuvant chemotherapy could be safely withheld in the group of patients with genetically low-risk hormonal breast cancers [@B143]. Further in-depth analysis of gene expression showed how immune cell-specific gene patterns could be used to define the fraction of infiltrating immune cells within 7,270 breast cancer profiles. The data also identified associations between different tumor compositions and therapy response as well as the outcome for known breast cancer subtypes [@B144]. Besides diversifying on single cancer types, integrative omics analysis can identify molecular patterns across cancer types. The Cancer Genome Atlas (TCGA) consortium, for instance, has compiled transcription and genomic profiling of more than 500 tumor samples each for 11 cancer types [@B145]. Meta-analysis on all combined TCGA-data sets uncovered new insights into shared features and common oncogenic drivers across tumor types and was used to classify tumors as being either largely driven by mutations or chromosomal aberrations [@B146]. The potential of integrative omics to yield new imaging targets was indicated by an explorative study. Combined analyses of microarray database Oncomine and Gene Ontology identified not only known imaging targets (*e.g.* HER2 in breast cancer) but also potential imaging targets to differentiate between normal and cancer tissues in six different cancer types including MUC1 in ovarian cancer [@B138]. The studies mentioned above confirmed previously established profiles, and more importantly, uncovered sub-classifications with distinct biological features, disease characteristics, and prognosis.

The studies above mainly used genomic and transcriptomic analyses, whereas technological advances have significantly improved the sensitivity and resolution of high-throughput proteomics [@B147]. Genomic and proteomic integration was recently applied in a large-scale analysis of TCGA colorectal cancer data [@B148]. Five unique protein signatures were identified, which confirmed established genomic signatures and revealed clinically relevant cancer sub-populations [@B148]. A similar approach was employed for the breast cancer TCGA cohort that also included phospho-proteomic analysis linking genetic alterations to changes in phosphorylated kinases [@B149]. To a certain degree, protein expression is expected to resemble gene transcription levels, especially in the case of CNAs, resulting in gene amplifications or deletions [@B150]. However, the proteogenomic analysis of TCGA data showed very often protein levels did not correlate well with mRNA levels or CNAs, underscoring the need for proteomic data to validate and further improve genetics-based classifications. This notion is particularly important for genomics-based selection of biomarkers intended for use in tissue samples or imaging. Taken together, omics studies have shown that (epi)genetic alterations give rise to a wide range of new molecular-based cancer classifications and large-scale genomic and proteomic analyses can support their identification.

Many biomarkers are used for patient stratification before treatment, however, they are not necessarily suitable for patient follow-up during and after treatment. In contrast to molecular imaging that allows for multiple, non-invasive whole body scans over time, genomic biomarkers are limited by the number of invasive re-biopsies for follow-up sampling and not necessarily informative for all lesions due to intra-tumor heterogeneity. This can potentially be improved by including molecular imaging in treatment decisions. For example, patients with ^89^Zr-trastuzumab PET HER2-positive pattern, showed more clinical benefit on T-DM1 therapy when compared to patients with a HER2 PET-negative pattern [@B107]. It is also of note, that detection of circulating tumor DNA (ctDNA) in blood might partly alleviate the difficulty of repeated invasive biopsies and allow for patient follow-up during treatment by retrospective analysis of serially obtained samples. For instance, a *de novo EGFR*mutation in exon 21 could be identified in circulating tumor DNA of a patient with recurrent ovarian cancer [@B151]. Similarly, the emergence of *EGFR*-T790M mutation was detected prior to progressive disease by serial measurement of ctDNA in plasma of NSCLC patients and was associated with worse overall survival [@B152].

An alternative strategy to discover therapy response biomarkers would involve pre- and post-treatment analysis of the proteomic make-up of tumors from responders versus non-responders. Such an approach would define proteins that dynamically change depending upon the efficacy of treatment and as such might be used as effect sensor biomarkers. Pre-clinical imaging studies have shown the feasibility of monitoring drug-induced changes in protein expression with radionuclide imaging, such as the successful imaging of increased expression of EGFR and HER3 following treatment with PI3K/AKT TKIs using ^64^Cu-antibody F(ab\')~2~ fragments [@B119]. Using this approach, potential effect sensors identified in omics studies could be validated with molecular imaging. However, large-scale proteome analysis of tumor samples about treatment is not widely performed, mainly due to the difficulty in obtaining post-treatment samples. Such analyses are certainly warranted to identify reliable markers for treatment response.

Although molecular profiling studies have provided valuable insights in cancer subtypes, the question remains whether the profiles can be reliably measured with standard clinical techniques and if they truly improve the survival outcomes. Recent clinical trials have shown the feasibility of treatment based on selected biomarkers panels, whole genome, or proteome analysis. For example, the BATTLE trial assessed the feasibility of a selected set of genomic and proteomic biomarkers for erlotinib treatment, including *EGFR* mutations or CNA analysis, to guide treatment decision for NSCLC patients [@B153]. At a larger scale, the WINTHER trial aims at full genomic analysis to stratify patients with so-called \'actionable alterations\', mutations that can be targeted with approved or experimental treatments [@B154]. Another example is the CPCT initiative in which next generation sequencing of tumor samples was performed to guide drug choice for patients with metastatic disease [@B155]. It is conceivable that omics-based screening will identify more patients with actionable alterations, leading to incremental knowledge and increasingly predictive biomarker profiles. To this end, molecular imaging could play a role in biomarker-driven studies that focus on alterations that lead to changes in expressed proteins. To clinically test treatments based on molecular biomarkers, trial designs are adapted to enroll patients with rare mutations from multiple cancer types in so-called basket clinical trials. Using such a design, patients from 7 different cancer types harboring a *BRAF*-V600E mutation could be treated with the BRAF inhibitor vemurafenib [@B156]. The recently launched TAPUR study (NCT02693535) encompasses 15 basket trials for patients with rare mutations. Amongst these are trials for patients with *EGFR*-mutated tumors to be treated with erlotinib, *EGFR*-wt tumors without any downstream *RAS* or *RAF* mutations with cetuximab, and treatment with trastuzumab and pertuzumab for patients with tumors harboring *HER2* amplifications. These developments will give an indication of the added value of omics for trial designs and treatment guidance and offer a unique opportunity for molecular imaging to be incorporated in future profiling studies.

Platform integration to identify novel biomarkers
-------------------------------------------------

Biomarkers are increasingly a part of clinical testing for classification of cancer and differentiation into relevant subgroups. Activating *EGFR* mutations are targeted for effective treatment with TKIs erlotinib or gefitinib in NSCLC while *ALK*mutations or *ROS1* translocations define a subgroup responding to crizotinib [@B157]. Other prototypical examples of genomic biomarker-based guidance for treatment choice are *BCR-ABL* translocations in chronic myeloid leukemia treated with imatinib, *BRCA1/2* mutations in ovarian cancer treated with PARP inhibitors, and *BRAF-*V600E mutations in melanoma treated with BRAF inhibitors [@B158]-[@B160]. Besides these genomic biomarkers, many tumor-expressed protein biomarkers have been reported, including HER2, estrogen receptor (ER), and progesterone receptor (PR) in breast cancer, and c-KIT in gastro-intestinal stromal tumors [@B161]. Interestingly, these protein targets (except c-KIT) can be successfully monitored in the clinic using a diverse panel of molecular imaging techniques for HER2, ER, and PR [@B94], [@B162], [@B163]. Despite the plethora of biomarkers reported in the literature, only a relatively small number has been approved for clinical use [@B161]. However, a renewed focus in precision medicine to develop targeted drugs together with matched biomarkers should improve the utility and numbers of biomarkers in the clinic [@B157]. We anticipate that by providing insight into whole body and temporal expression of biomarkers, molecular imaging approaches can be one of the platforms to validate and apply new and existing tumor markers.

Genomic changes do not translate to phenotypic changes per se due to, for instance, regulation of RNA translation or protein function affected by post-translational modifications (PTMs). PTMs, such as phosphorylation and ubiquitination, can greatly affect the activity, stability, and function of proteins and can be highly dynamic modifications. Proteogenomic analyses by the Clinical Proteome Tumor Analysis Consortium (CPTAC) on CRC and breast cancer TCGA tumor specimens showed that translational factors could be quantitatively analyzed by proteomics and integrated with genomics to validate and improve molecular profiling [@B148],[@B149]. Integration of multiple platforms allows for more depth of analysis and stringent selection, potentially leading to more successful biomarkers [@B164]. The addition of proteomics to existing genomic platforms can determine whether genomic markers are functionally expressed, allows for correlation of metabolic and enzymatic processes with genomic profiles, and can be used to follow-up on serum biomarkers and effect sensors in time. Ultimately, this could lead to robust molecular imaging candidates to visualize drug resistance or tumor responses (Figure [3](#F3){ref-type="fig"}).

To find new molecular imaging targets, proteomics can be used for validation of selected genomic markers or identification of new markers based upon the integration of proteomic and genomic data. For validation or measurement of a selected number of biomarkers after the initial discovery, targeted MS techniques such as multiple reaction monitoring-MS (MRM-MS) or reverse phase protein array (RPPA) are most suitable, whereas new biomarkers are better identified with quantitative proteomics. Thus far, MRM-MS has been mostly employed for serum biomarkers such as prostate-specific antigen or changes in metabolism [@B165]. Serum biomarkers are extensively explored using proteomics and employed as diagnostic tools. However, serum biomarkers mostly reflect tumor load and do not provide information on inter- and intra-tumor heterogeneity making them less suitable as molecular imaging targets. Nevertheless, serum analysis can be integrated with genomics to study treatment responses. For instance, by analyzing temporal changes in gene expression and serum metabolites in an *EGFR*-L828R-T790M-driven mouse tumor model, it was possible to identify changes in metabolic pathways, such as the glutathione pathway essential for tumor response to EGFR TKI afatinib alone or in combination with the mTOR inhibitor rapamycin [@B166]. As glutamine is a precursor of the glutathione pathway, molecular imaging with ^18^F-glutamine PET in NSCLC and breast cancer patients might facilitate monitoring drug-induced changes in this pathway [@B167]. Thus, similar approaches can be used to measure changes in metabolic or enzymatic processes identified by genomics and confirmed by proteomic measurements. In addition to imaging of the prostate specific membrane antigen (PSMA) to visualize prostate cancer, the enzymatic activity of PSMA could be visualized with urea-based tracers, which are metabolized by PSMA [@B152], [@B153]. Such studies point to cellular processes underlying biomarkers that might be used for molecular imaging.

RPPA is a promising technique for analysis of cellular biomarker panels, as it allows multiplexed assessment of markers limited only by the availability of specific antibodies. The combination of transcriptomic, genomic, and drug sensitivity data by RPPA analysis of 71 proteins in 84 NSCLC cell lines showed that sensitivity to EGFR inhibition correlated better with activated EGFR levels than EGFR abundance [@B160]. These data are in concordance with the correlation between activated EGFR and EGFR TKI sensitivity found in clinical studies. As another example, a pattern of high AXL expression and c-MET activation was identified using RPPA in breast cancer tissues supposedly driving proliferation [@B170]. Gene expression analysis studies have further led to the identification of AXL as a driver of resistance to EGFR TKIs in HNSCC and NSCLC models [@B171], [@B172]. Considering that AXL imaging has already been performed with ^64^Cu-labeled [@B173] and NIRF-dye Cy5.5-conjugated AXL antibodies [@B174] in AXL-positive A549 human NSCLC xenografts in mice, this proliferation pathway and resistance mechanism to EGFR TKIs could potentially be monitored by non-invasive imaging. RPPA has been employed on a large scale targeting nearly 200 proteins and phosphorylated variants on 4,379 tumor samples, largely from 11 TCGA cancer cohorts and 3 independent cohorts [@B175]. Although these data, so far only used to uncover pan-cancer proteomic relations in the TCGA cohorts, still provide a unique opportunity to integrate genomic TCGA analyses with proteomic data across multiple tumor types [@B176].

Identification of novel prognostic biomarkers or protein-based early effect sensors should not depend on fixed, preselected, antibodies used in RPPA and is better studied with a quantitative MS-based proteome-wide analysis. This can be performed using either isotope or chemical labeling or by label-free quantitation. Proteogenomic analysis of the TCGA CRC cohort was performed with label-free analysis using spectral counting and expression levels of protein were quantified in relation to all measured samples [@B148]. To accurately quantify protein expression changes or PTMs, knowledge of control or standardized expression levels is essential. To this end, protein-labeling techniques can be employed together with MS, which utilizes incorporation of stable isotopes in cell lines. For example, SILAC-MS quantifies ratios between proteins derived from stable isotope-labeled cell lines and their unlabeled counterparts from control cell cultures. This technique can thus be used to measure protein dynamics when a certain treatment is applied to one of the cell cultures [@B177]. Alternatively, isotope labeling can be performed post-treatment on cells or patient tissues using standardized SILAC-labeled reference samples or chemical labeling using isobaric tags for the relative and absolute quantitation (iTRAQ) method [@B178]. Using SILAC-based proteomics, increased levels of EGFR, Clusterin-CLU, and HADHB were found as potential biomarkers in trastuzumab-resistant breast cancer cell lines compared to their parental controls [@B179]. An early proteomic response to EGFR inhibition by gefitinib in human NSCLC cell line A431 was also investigated using SILAC-MS identifying a panel of 15 membrane proteins upregulated after gefitinib treatment [@B180]. Although not clinically validated, these proteins identified in both studies were suggested as early markers of resistance to trastuzumab. Quantitative proteomics is, therefore, a promising discovery platform for new molecular imaging effect sensors by analyzing drug-induced changes in proteomes of cancer cells.

A largely untouched area of biomarkers is PTMs of proteins, that can be identified using MS. SILAC- and iTRAQ-based MS strategies, which are highly effective in quantifying changes in multiple PTMs simultaneously, such as changes in phosphorylation, glycosylation, or ubiquitination [@B181]. PTMs are particularly interesting molecular markers as they portray the underlying, highly dynamic, biologic processes in cancer. For example, the extensive phospho-proteome analysis was performed to map EGFR signaling in relation to the sensitivity to HER family inhibitors. This approach confirmed alterations in established downstream signaling after EGFR TKI treatment, while feedback pathways involving HER2 and HER3, as well as changes in autophagy pathways were identified [@B166], [@B167]. Furthermore, SILAC phospho-proteomic analysis detected high levels of phosphorylated EGFR in *EGFR-*wt pancreatic cancer cell lines sensitive to erlotinib, suggesting phosphorylated EGFR as a predictive marker for erlotinib treatment when *EGFR* mutations are absent [@B184]. Using iTRAQ labeling of 105 TCGA breast cancer samples with corresponding genomic and clinical data, new correlations between genetic alterations (*e.g.* CNAs) and protein translation were found. For instance, loss of chromosome arm 5q containing *SKP1*and*CETN3*in basal breast cancers was shown as the potential cause of increased expression of EGFR and Src [@B149]. Furthermore, CNAs could also be linked to changes in phosphorylation, as *HER2* amplification induced over-expression and activation of not only HER2 but also of the surrounding genes *CDK12*, *MED1*, and *GRB7* [@B149]. Assuming the availability of specific probes for detection of PTMs, molecular imaging, for example using TAT-modified antibody strategies, would allow for direct analysis of pathway activation status, and may be more informative than analysis of the plain abundance of pathway components.

Developments in genomic and proteomic platforms will continue to improve biomarker discovery that will lead to implementation in clinical studies. With the existing and expanding data from these studies, molecular imaging targets can be identified that can potentially guide treatment decisions.

Discussion
==========

Development of targeted therapies and their implementation in clinical practice can be aided by molecular testing of tumor biopsies or blood-borne markers. Complementary to these diagnostic tools, we described how molecular imaging techniques could provide valuable information on whole body distribution of drug targets to aid the assessment of drug efficacy during treatment. Measuring target presence and dynamics across multiple tumor lesions could be highly relevant to assess drug uptake, especially regarding marker-dependent agents using toxic payloads such as ADCs. Besides radionuclide-based imaging strategies, advances in optical imaging might enable simultaneous visualization of multiple markers at organ-level resolution, removing the radiation burden and lowering production costs. To unveil many relevant intracellular processes, technical advances should be aimed at bringing high affinity, large molecular weight probes, such as antibodies and analogs past cellular membranes, allowing high-contrast visualization of intracellular processes in tumor cells. Whether molecular imaging of oncogenic growth factor receptor imaging is sufficient to assess treatment efficacy and resistance of HER family-driven cancers is currently being investigated in clinical trials.

Many imaging agents are directed to commonly used tumor markers or drug targets to acquire a better understanding of target distribution and behavior. However, this array of markers can be greatly expanded by making use of integrative omics approaches that link patient and tumor characteristics to genomic and proteomic analysis. From these efforts, molecular markers have been discovered that distinguish specific subsets of cancers that could be assessed by molecular imaging. Similarly, radiomics approaches combine patient and tumor characteristics, including mutation status, for computational analysis of molecular imaging data to discover prognostic or predictive features for treatment response and outcome. Key oncogenic tumor targets or distinguishing tumor markers identified by omics approaches are not often the ideal extracellular imaging targets. However, new technologies in intracellular localization of imaging tracers might enable monitoring the activation status of these relevant biological components. Lastly, there is an unmet opportunity for pre- and post-treatment imaging of effect sensors that can be discovered by omics analysis of serially obtained tumor samples.

In summary, an extensive arsenal of molecular probes is already available to image HER family members and related proteins. Coupled to omics-based discovery platforms, this can open up an arsenal of other novel tracers for monitoring treatment efficacy and drug resistance.
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![**Involvement of HER family in cancer treatment and resistance**A) Ligand binding to HER family members induces homo- or hetero-dimerization. Transphosphorylation of kinase domains then induces a downstream phosphorylation cascade including PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways. B) Cancers that dependent on HER family activity can be treated using mAbs or TKIs. Binding of mAbs can inhibit receptor function by preventing dimerization or ligand binding, or by inducing internalization and degradation. Small molecule TKIs inhibit transphosphorylation by blocking the ATP binding pockets, either of the receptors or downstream signaling nodes. C) Multiple mechanisms of resistance to HER family-directed therapy have been discovered. Expression of truncated variant HER2-p65 or EGFR*vIII* prevent antibody binding, while gatekeeper mutations in *EGFR* limit binding of erlotinib or gefitinib to TK domain of EGFR (left panel). Inhibition of HER signaling can be restored by interactions with non-HER family members, namely c-MET, IGF1R or Src (middle panel). Lastly, compensatory feedback mechanism exist within the HER family, where inhibition of HER2 induces expression and activation of HER3 to restore PI3K/AKT signaling (right panel).](thnov07p2111g001){#F1}

![**Molecular imaging strategies of HER family proteins**A-C) Expression of cell membrane bound HER2 can be imaged by specific binding of ^89^Zr-trastuzumab to HER2, leading to residualizing of ^89^Zr in tumor cells due to internalization and subsequent degradation of the antibody-receptor complex. HSP90 inhibition by NVP-AUY922 leads to destabilization and degradation of HER family proteins at the plasma membrane, leading to lower antigen availability and reduced tracer uptake. B) PET images of mice scanned with ^89^Zr-trastuzumab before (Top) and after (Bottom) treatment with NVP-AUY922, quantified for 144 hours [@B122]. C) ^89^Zr-trastuzumab PET imaging of a metastatic breast cancer patient before (Top) and after 3 weeks of NVP-AUY922 treatment (Middle), with CT-scan prior to treatment shown in Bottom panel. Quantification of all lesions shows a heterogeneous response with a total average decrease in ^89^Zr-trastuzumab uptake after 3 weeks of NYP-AUY922 treatment [@B125]. D,E) Higher accumulation of ^11^C-erlotinib occurs in tumors with specific activating mutations in EGFR due to its higher affinity to the mutated TK compared to *EGFR*-wt. NSCLC tumors with exon-19 deletion (series A) showed higher uptake compared to *EGFR*-wt tumors (series B). A1-B1: CT fused-parametric ^11^C-erlotinib V~t~; A2-B: CT; A3-B3: ^18^F-FDG [@B71] F,G) Imaging of HER3 levels using ^64^Cu-DOTA-F(ab\')~2~can be utilized as effect sensor of AKT inhibitors, as GDC-0068 specifically induces expression of HER3, but not EGFR, as feedback mechanism of AKT inhibition in mouse xenografts after 72h of treatment [@B119]. H,I) Imaging of intracellular processes can be facilitated by TAT-modified antibodies. ^111^In-DTPA-anti-yH2AX-Tat antibodies visualized the formation of DNA damage foci marked by γ-H2AX treatment upon treatment with irradiation of DNA damaging agent bleomycin in mouse xenografts [@B129].](thnov07p2111g002){#F2}

![**Omics-based strategies to facilitate discovery of novel molecular imaging targets**Tissue or serum samples collected from patients, or from other *in vivo*and *in vitro* sources, can be analyzed by genomic, transcriptomic, and proteomic discovery platforms. The resulting profiles can then be combined by integrative omics approaches to develop molecular-based tumor classifications and discover potential informative biomarkers. From this integrative approach new protein targets or mutations could be discovered that distinguish tumor from benign tissue. Similarly, analyzing pre- and post-treatment profiles could potentially lead to discovery of effect sensors that signify response to treatment or emergence of resistance pathways.](thnov07p2111g003){#F3}
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Overview of ongoing clinical trials with molecular imaging of HER family members and related targets

  ------------------------------- -------------------------------------------------------------------------------------------
  **Target expression imaging**   
  [EGFR]{.ul}                     ClinicalTrials.gov identifiers
  ^89^Zr-cetuximab                NCT01691391, NCT02117466, NCT00691548
  ^89^Zr-panitumumab              NCT02192541, NCT00326495
  800CW-cetuximab                 NCT01987375, NCT02736578
  800CW-panitumumab               NCT02415881
  [HER2]{.ul}                     
  ^89^Zr-trastuzumab              NCT01420146, NCT02286843, NCT01832051, NCT02065609, NCT01957332, NCT02023996, NCT01565200
  ^111^In-pertuzumab              NCT01805908
  ^68^Ga-ABY-025                  NCT02095210, NCT01858116
  [HER3]{.ul}                     
  ^89^Zr-RO5479599                NCT01482377
  ^89^Zr-GSK2849330               NCT02345174
  [VEGF-A]{.ul}                   
  ^89^Zr-bevacizumab              NCT01894451
  800CW-bevacizumab               NCT02113202, NCT01972373, NCT02129933 NCT01508572, NCT02583568, NCT02743975
  **Drug accumulation imaging**   
  [EGFR]{.ul}                     
  700DX-cetuximab (RM-1929)       NCT02422979
  [HER2]{.ul}                     
  ^89^Zr-trastuzumab              NCT01565200
  ^64^Cu-trastuzumab              NCT01939275
  ^64^Cu-MM-302                   NCT01304797
  **Mutant specific imaging**     
  [EGFR]{.ul}                     
  ^11^C-erlotinib                 NCT02111889
  ------------------------------- -------------------------------------------------------------------------------------------

###### 

Overview of preclinical and clinical tracers

  Tracer                                                            Modality   Scaffold            Study type    Target                  Remarks                                                                                                                                                                                       Ref        
  ----------------------------------------------------------------- ---------- ------------------- ------------- ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- --
  **Target expression**                                                                                                                                                                                                                                                                                                                           
  ^64^Cu-cetuximab                                                  PET        mAb                 Preclinical   EGFR                    Correlation with EGFR expression xenografts                                                                                                                                                   62         
  ^111^In-cetuximab                                                 SPECT      mAb                 Preclinical   EGFR                    Correlation with EGFR expression xenografts                                                                                                                                                   63         
  ^111^In-f(ab\')~2~-cetuximab                                      SPECT      f(ab\')~2~          Preclinical   EGFR                    Correlation with EGFR expression xenografts                                                                                                                                                   61         
  ^89^Zr-cetuximab                                                  PET        mAb                 Preclinical   EGFR                    No correlation with EGFR expression xenografts                                                                                                                                                64         
  ^64^Cu-cetuximab                                                  PET        mAb                 Preclinical   EGFR                    No correlation with EGFR expression xenografts                                                                                                                                                65         
  ^89^Zr-cetuximab                                                  PET        mAb                 Clinical      EGFR                    Tumor uptake in metastatic colorectal patients                                                                                                                                                67         
  IRDye 800CW-cetuximab                                             NIRF       mAb                 Preclinical   EGFR                    Detection of breast cancer xenograft lesions                                                                                                                                                  79         
  IRDye 800CW-cetuximab                                             NIRF       mAb                 Preclinical   EGFR                    Detection of implanted EGFR-positive lesions in colonoscopy of a resected human colon                                                                                                         82         
  IRDye 800CW-cetuximab                                             NIRF       mAb                 Clinical      EGFR                    Intraoperative tumor detection in HNSCC patients                                                                                                                                              83         
  IRDye 800CW-cetuximab                                             NIRF       mAb                 Clinical      EGFR                    Correlation between *ex vivo* fluorescent signal and EGFR density per IHC in excised HNSCC patient tumors                                                                                     84         
  ^89^Zr-imgatuzumab                                                PET        mAb                 Preclinical   EGFR                    Influence of circulating shed EGFR on tracer tumor uptake and kinetics                                                                                                                        66         
  IRDye 800CW-7D12                                                  NIRF       nanobody            Preclinical   EGFR                    Detected EGFR overexpressing xenografts                                                                                                                                                       80         
  IRDye 800CW-7D12                                                  NIRF       nanobody            Preclinical   EGFR                    Intraoperative visualization of orthotopic primary tongue tumor xenografts and cervical lymph node metastases                                                                                 81         
  IRDye 800CW-panitumumab                                           NIRF       mAb                 Preclinical   EGFR                    Detection of breast cancer xenograft lesions                                                                                                                                                  79         
  IRDye 800CW-panitumumab                                           NIRF       mAb                 Preclinical   *EGFR*-wt/ EGFR*vIII*   Similar affinity to *EGFR*-wt and EGFR*vIII-*expressing xenografts                                                                                                                            75         
  IRDye 800CW-EGFR affibody                                         NIRF       affibody            Preclinical   *EGFR*-wt/ EGFR*vIII*   Similar affinity to *EGFR*-wt and EGFR*vIII-*expressing xenografts                                                                                                                            75         
  IRDye 800CW-EGF                                                   NIRF       ligand              Preclinical   *EGFR*-wt/ EGFR*vIII*   Accumulated in *EGFR-*wt, but not EGFR*vIII*-expressing xenografts                                                                                                                            75         
  ^99m^Tc-3C10                                                      SPECT      mAb                 Preclinical   *EGFR*-wt/ EGFR*vIII*   Accumulated more in EGFR*vIII* than in *EGFR*-wt xenografts                                                                                                                                   77         
  IRDye 680RD-biotin-4G1                                            NIRF       mAb                 Preclinical   *EGFR*-wt/ EGFR*vIII*   Accumulated more in EGFR*vIII* than in *EGFR*-wt xenografts                                                                                                                                   78         
  ^124^I-IMP-R4-ch806                                               PET        mAb                 Preclinical   EGFR*vIII*              Accumulated in EGFR*vIII*-transfected U87MG xenografts                                                                                                                                        68         
  ^11^C-erlotinib                                                   PET        TKI                 Preclinical   *EGFR*-wt/ mutEGFR      Accumulation more in exon 19 and 21 mutated than in *EGFR*-T790M and *EGFR*-wt xenografts                                                                                                     68-70      
  ^11^C-erlotinib                                                   PET        TKI                 Clinical      mutEGFR                 Volume of distribution higher in NSCLC patients with *EGFR* exon 19 deletion than in lesions of patients without activating mutations                                                         71         
  ^11^C-erlotinib                                                   PET        TKI                 Clinical      mutEGFR                 3 out of 4 patients with ^11^C-erlotinib PET positive lesions responded to erlotinib, while best response in ^11^C-erlotinib PET negative lesions was stable disease in 2 out of 9 patients   72         
  ^11^C-erlotinib                                                   PET        TKI                 Clinical      mutEGFR                 Case report of high ^11^C-erlotinib uptake in brain metastases of *EGFR* exon 19 mutated NSCLC patient which responded to erlotinib                                                           73         
  ^18^F-afatinib                                                    PET        TKI                 Preclinical   EGFR/HER2               Higher accumulation in EGFR-wt and EGFR-exon 19 deletion, compared to EGFR-T790M xenografts                                                                                                   74         
  ^89^Zr-trastuzumab                                                PET        mAb                 Preclinical   HER2                    Specific uptake in HER2-positive xenografts                                                                                                                                                   86, 88     
  ^89^Zr-trastuzumab                                                PET        mAb                 Clinical      HER2                    Detection of lesions in HER2-positive breast cancer patients                                                                                                                                  94         
  ^111^In-trastuzumab                                               SPECT      mAb                 Clinical      HER2                    Detection of lesions in HER2-positive breast cancer patients                                                                                                                                  93         
  ^89^Zr-pertuzumab                                                 PET        mAb                 Preclinical   HER2                    Specific uptake in HER2-positive xenografts                                                                                                                                                   79         
  ^111^In-ABY-002                                                   SPECT      affibody            Clinical      HER2                    Detection of lesions in HER2-positive breast cancer patients                                                                                                                                  90         
  ^68^Ga-ABY-002                                                    PET        affibody            Clinical      HER2                    Detection of lesions in HER2-positive breast cancer patients                                                                                                                                  90         
  ^68^Ga-2Rs15d                                                     PET        nanobody            Clinical      HER2                    Detection of lesions in HER2-positive breast cancer patients                                                                                                                                  91         
  ^111^In-Fab-PEG~24~-HRG                                           PET        Fab/HRG construct   Preclinical   HER2/ HER3              HER3 and HER2-mediated uptake in xenografts                                                                                                                                                   100        
  ^89^Zr-lumretuzumab                                               PET        mAb                 Preclinical   HER3                    HER3-specific uptake in xenografts                                                                                                                                                            95         
  ^89^Zr-lumretuzumab                                               PET        mAb                 Clinical      HER3                    Tumor uptake in patients with solid tumors, as well as tumor uptake before and after administrating therapeutic doses cold lumretuzumab                                                       102        
  ^64^Cu-DOTA-HER3 F(ab\')~2~                                       PET        f(ab\')~2~          Preclinical   HER3                    HER3-specific uptake in xenografts                                                                                                                                                            96         
  ^68^Ga-HEHEHE-Z~08698~                                            PET        affibody            Preclinical   HER3                    HER3-specific uptake in xenografts                                                                                                                                                            97         
  ^111^In-HEHEHE-Z~08698~                                           SPECT      affibody            Preclinical   HER3                    HER3-specific uptake in xenografts                                                                                                                                                            98         
  ^99m^Tc-HEHEHE-Z~08699~                                           SPECT      affibody            Preclinical   HER3                    HER3-specific uptake in xenografts                                                                                                                                                            99         
  ^111^In-HEHEHE-Z~08699~                                           SPECT      affibody            Preclinical   HER3                    HER3-specific uptake in xenografts                                                                                                                                                            97         
  ^64^Cu-patritumab                                                 PET        mAb                 Clinical      HER3                    Tumor uptake in patients with solid tumors                                                                                                                                                    101        
  **Accumulation**                                                                                                                                                                                                                                                                                                                                
  IRDye 700DX-cetuximab                                             NIRF       mAb                 Preclinical   EGFR                    Photoimmunotherapy and detection of lesions                                                                                                                                                   103        
  ^89^Zr-cetuximab                                                  PET        mAb                 Preclinical   EGFR                    Prediction of accumulation for ^88^Y- and ^177^Lu-labeled cetuximab                                                                                                                           104        
  ^64^Cu-MM-302                                                     PET        liposome            Preclinical   HER2                    Predict deposition, kinetics and efficacy of the parental doxorubicin-loaded liposome in xenografted mice and primates                                                                        105, 106   
  ^89^Zr-trastuzumab                                                PET        mAb                 Clinical      HER2                    ^89^Zr-trastuzumab scans to determine intra/interpatient HER2 heterogeneity and (non-)responders to T-DM1 therapy                                                                             107        
  ^89^Zr-trastuzumab                                                PET        mAb                 Preclinical   HER2                    Increased uptake of^89^Zr-trastuzumab after N-acetylcysteine treatment of MUC4-expressing xenografts                                                                                          111        
  ^89^Zr-pertuzumab                                                 PET        mAb                 Preclinical   HER2                    Enhanced residualization of ^89^Zr-pertuzumab with concurrent trastuzumab treatment in xenografted mice                                                                                       87         
  ^89^Zr-trastuzumab/^89^Zr-Bevacizumab / ^89^Zr-IgG                PET        mAb                 Preclinical   HER2/ VEGF/ generic     Anti-angiogenic agent bevacizumab decreased general antibody tracer uptake in xenografts                                                                                                      113        
  ^111^In-trastuzumab/ ^125^I-trastuzumab/^111^In-IgG/ ^125^I-IgG   SPECT      mAb                 Preclinical   HER2/ generic           Anti-angiogenic agent B20-4.1 decreased general antibody tracer uptake in xenografts                                                                                                          112        
  ^89^Zr-MMOT0530A                                                  PET        mAb                 Preclinical   mesothelin              Tumor accumulation of naked antibody version of ADC DMOT4039A                                                                                                                                 108        
  ^89^Zr-MMOT0530A                                                  PET        mAb                 Clinical      mesothelin              ^89^Zr-MMOT0530A uptake as predictor for clinical response to the corresponding ADC DMOT4039A                                                                                                 109        
  **Treatment effects**                                                                                                                                                                                                                                                                                                                           
  ^64^Cu-DOTA Cetuximab F(ab\')~2~                                  PET        f(ab\')2            Preclinical   EGFR                    EGFR upregulation after PI3K inhibitor GDC-0941 and AKT inhibitor GDC-0068 treatment                                                                                                          119        
  ^89^Zr-MEHD7945A                                                  PET        mAb                 Preclinical   EGFR/ HER3              EGFR and HER3 upregulation after AKT inhibition by GDC-0068                                                                                                                                   126        
  ^89^Zr-trastuzumab                                                PET        mAb                 Preclinical   HER2                    Downregulation of HER2 expression through afatinib treatment                                                                                                                                  120        
  ^89^Zr-trastuzumab                                                PET        mAb                 Preclinical   HER2                    HER2 downregulation after HSP90 inhibition with NVP-AUY-922                                                                                                                                   122        
  ^89^Zr-trastuzumab                                                PET        mAb                 Preclinical   HER2                    HER2 downregulation after HSP90 inhibition with PU-H71                                                                                                                                        124        
  ^89^Zr-trastuzumab                                                PET        mAb                 Clinical      HER2                    HER2 downregulation after HSP90 inhibition with NVP-AUY922 in HER2-positive breast cancer patients                                                                                            125        
  ^89^Zr-trastuzumab F(ab\')~2~                                     PET        f(ab\')~2~          Preclinical   HER2                    Upregulation and stabilization of HER2 at the plasma membrane after lapatinib treatment                                                                                                       121        
  ^89^Zr-trastuzumab F(ab\')~2~                                     PET        f(ab\')~2~          Preclinical   HER2                    HER2 downregulation after HSP90 inhibition with 17AAG                                                                                                                                         121        
  AlexaFluor 680-Z~Her2:342~                                        NIRF       affibody            Preclinical   HER2                    HER2 downregulation after HSP90 inhibition with 17-DMAG                                                                                                                                       123        
  ^64^Cu-DOTA-HER3 F(ab\')~2~                                       PET        f(ab\')~2~          Preclinical   HER3                    HER3 upregulation after AKT inhibition by GDC-0068                                                                                                                                            119        
  ^89^Zr-mAb391                                                     PET        mAb                 Preclinical   IG1R                    IGF1R downregulation after HSP90 inhibition with NVP-AUY-922                                                                                                                                  115        
  ^89^Zr-bevacizumab                                                PET        mAb                 Preclinical   VEGF                    VEGF-A downregulation after heat shock protein-90 inhibition NVP-AUY922                                                                                                                       114, 115   
  ^89^Zr-bevacizumab                                                PET        mAb                 Preclinical   VEGF                    Downregulation of VEGF-A through everolimus treatment                                                                                                                                         116        
  ^89^Zr-bevacizumab                                                PET        mAb                 Clinical      VEGF                    Downregulation of VEGF-A through everolimus treatment                                                                                                                                         117        
  ^89^Zr-ranibizumab                                                PET        f(ab\')~2~          Preclinical   VEGF                    Sunitinib treatment-induced changes in VEGF-A tumor levels                                                                                                                                    118        
  **Intracellular processes**                                                                                                                                                                                                                                                                                                                     
  ^111^In-anti-p27^kip1^-TAT                                        SPECT      mAb                 Preclinical   p27^kip1^               Upregulation of p27^kip1^ after trastuzumab treatment                                                                                                                                         128        
  ^111^In-anti-γH2AX-TAT                                            SPECT      mAb                 Preclinical   phospho- H2AX           Detection of DNA breaks induced by chemo and radiotherapy                                                                                                                                     129        
  ^111^In-anti-γH2AX-TAT                                            SPECT      mAb                 Preclinical   phospho- H2AX           Detection of DNA breaks induced during tumorigenesis of breast cancer in BALB/C *Neu-*T mice                                                                                                  131        
  ^89^Zr-anti-γH2AX-TAT                                             PET        mAb                 Preclinical   phospho- H2AX           Detection of DNA breaks induced by chemo and radiotherapy                                                                                                                                     130        
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